Vancouver, British Columbia, Canada, May 3, 2023– Satisfai Health Inc. (Satisfai), a leading medical company providing artificial intelligence solutions in the field of Gastroenterology, announces the addition of Ms. Solveig Johannessen as Chief Strategy Officer and Mr. Ben Brzezynski as Vice President of Business Development.

Ms. Johannessen and Mr. Brzezynski will focus on the Company’s mission to become the leading global provider of AI-powered clinical decision support and precision medicine solutions in Gastroenterology, GI Endoscopy, and Intestinal Ultrasound.

Ms. Johannessen is an accomplished leader with over two decades of experience designing and delivering innovative products, services, and customer experiences. As the Chief Strategy Officer at Satisfai, Solveig is responsible for developing and executing the Satisfai strategic plans to drive growth and profitability, while also leading efforts to innovate and transform the business.

Mr. Brzezynski is an experienced business development professional in the software, medical AI, and digital health fields. As VP of Business Development at Satisfai, Ben will lead market development and commercial strategy for Satisfai’s clinical products and contract research and development services.

“With the addition of Solveig and Ben to our leadership team, we will innovate and evolve many aspects of our product and services roadmap and strategy, while driving growth and profitability,” said Dr. Michael Byrne, Chairman & CEO of Satisfai Health.

Ms. Johannessen previously held a leadership role in Customer Strategy & Applied Design at Deloitte Digital and founded a successful Vancouver-based consultancy focused on business transformation, product strategy and experience design for clients including Molecular You, Light AI, Microbiome Insights, Avnet, CHC Helicopter, Heli-One, Contextual Genomics, The Personalized Medicine Initiative, and Pacific Autism Family Centre. She also has extensive experience in aviation and energy R&D, where she developed and delivered multi-faceted customer experiences and service innovation.

Mr. Brzezynski led global business development for ThinkSono and Enlitic, and previously worked as a lead medical services agreement negotiator for the British Columbia Medical Association. He designed and led successful commercial initiatives for computer vision and natural language processing technologies in the medical imaging, medical procedure guidance and telemedicine fields. He has delivered innovative technologies to market in the United States, Canada, Japan, the United Kingdom, Turkey, and the UAE, where he worked with physicians ranging from general practitioners to subspecialists and medical informaticians.

About Satisfai Health

Satisfai is a leading medical solutions provider specializing in AI applications applied to large addressable markets in gastroenterology. Satisfai’s solutions deliver real-time medical image analysis, providing clinicians with decision support intelligence that dramatically improves patient outcomes. Satisfai is supported by a highly respected board of clinicians and key opinion leaders who operate at the top of their fields in the many focus areas within gastroenterology. Satisfai enjoys a strong voice on academic panels and leading GI societies, and direct access to prominent industry players seeking to adopt new AI technologies in gastroenterology. For more information, visit

Satisfai Health Contact:

Mr. Andrew Stibbs


[email protected] 

Solidifies Satisfai as one of the leading technology companies globally in artificial intelligence for gastroenterology

Vancouver, British Columbia, Canada, 21 November 2022 – Satisfai Health, Inc (“Satisfai”) today announces its strategic acquisition of Docbot, Inc’s portfolio of Intellectual Property and Assets which is complementary and accretive to Satisfai’s products and technology stack, focused in the field of artificial intelligence (AI) as applied to gastrointestinal endoscopy. In addition, key Docbot technical employees have been transferred to Satisfai.

The partnership enables advanced AI-fueled HD video capture, decision support, and clinical research tools for Alimentiv’s global clinical trial investigator site network.

London, Ontario, Canada, 5 October 2022 – Alimentiv Inc. (“Alimentiv”), Satisfai Health, Inc (“Satisfai”), and Virgo Surgical Video Solutions, Inc. (“Virgo”) today announced a strategic partnership to revolutionize central reading, data capture, decision support, and patient recruitment in the clinical trial domain for Inflammatory Bowel Disease (IBD) and allied GI conditions. Satisfai, a global leader in developing artificial intelligence solutions for gastroenterology, and Virgo, an industry leader in endoscopy video capture technology, will leverage their combined strengths to work in partnership with Alimentiv, a leading CRO in gastroenterology, to realize the full potential of AI-powered precision imaging in the GI clinical trials space.

Virgo Surgical Video Solutions, Inc. (“Virgo”) and Satisfai Health Inc. (“Satisfai”) today announced an exclusive partnership to revolutionize gastroenterology decision support and clinical research with AI-fueled, cloud-enabled endoscopic solutions. Virgo, the industry leader in endoscopy video capture technology, and Satisfai, a vanguard in developing artificial intelligence solutions for gastroenterology, will leverage their combined strengths to realize the full potential of AI-powered precision imaging that will revolutionize GI medicine.

Satisfai Health is pleased to announce a partnership with the International Bowel Ultrasound (IBUS) Group e.V. to develop Artificial Intelligence (AI) solutions for intestinal ultrasound (IUS) in patients with Inflammatory Bowel Disease (IBD), namely Crohn’s disease and Ulcerative Colitis.

Satisfai Health has signed an engagement letter appointing Fort Capital Partners as a Financial Advisor to the Company.  This appointment is in connection with the Company’s recent launch of its Series A private placement offering of common stock, the proceeds from which will be used to complete certain strategic technology acquisitions and continue to fund the build out of Satisfai’s Health’s AI team to deliver on the Company’s mission to become the global leader in providing AI solutions in Gastroenterology and GI Endoscopy.

Satisfai Acquires Software Developed at OTH Regensburg

Satisfai appreciates the further coverage of our successful collaboration with Dr. Helmut Messmann, Robert Mendel, and Christoph Palm and the entire teams at Ostbayerische Technische Hochschule RegensburgUniversitätsklinikum Augsburg .  Satisfai is excited to move forward on our plan to bring early detection of esophageal cancer using Artificial Intelligence to clinical practice. 

ASGE Journal Scan - AI Similar to Experts at Barrett's Optical Biopsy

Satisfai was pleased to see Dr. Prateek Sharma review our recent publication Artificial Intelligence Similar to Expert Endoscopists at Differentiating Between Mucocal and Submucosal Barrett’s Cancer (Ebigbo et al – Endoscopy, September 2021)

Satisfai Health Uses AI to Detect Early Esophageal Cancer

Recent Canadian coverage of Satisfai’s AI tool to detect early esophageal cancer is much appreciated but well founded as we work to broaden the Satisfai Health product roadmap to cover more of the GI tract. 

Satisfai Health acquires global license for AI software to detect early cancer in Barrett's Esophagus

Satisfai Health, a leading medical solutions provider specializing in artificial intelligence (AI) applications, particularly in Gastrointestinal Endoscopy, has acquired an exclusive global license from the University of Augsburg and the OTH Regensburg, Technical University of Applied Sciences, in Germany. 


Barrett's Esophagus Application Demo


Request a Demo

Dr. Reno Panaccione

Director of IBD

Dr. Panaccione is currently a Professor of Medicine, the Director of the Inflammatory Bowel Disease Clinic at the University of Calgary and Director of Gastroenterology Research.

Dr. Panaccione graduated from the University of Western Ontario (London, Ontario) with a degree in Medicine in 1993. He went on to complete his Internal Medicine and Gastroenterology training at the University of Western Ontario and is certified as a fellow of the Royal College of Physicians and Surgeons of Canada in both Internal Medicine and Gastroenterology. Dr. Panaccione completed advanced training in Inflammatory Bowel Disease at the Mayo Clinic in Rochester, Minnesota. He joined the faculty of Medicine at the University of Calgary in 1999. He is an internationally recognized expert in inflammatory bowel disease. He has lectured nationally and internationally on various topics in inflammatory bowel disease and has delivered over 200 lectures in the last five years.

He is the author of many peer-reviewed articles (~250) and book chapters (25) on inflammatory bowel disease. His special interest lies in the fields of advanced therapies, biological therapy, and delivery of care through the implementation of clinical trials. He is a recognized authority on the use of biologics and has co-authored numerous guidelines on the management of inflammatory bowel disease for the Canadian Association of Gastroenterology. He actively participates in clinical trials of new therapeutic agents in Crohn’s disease and ulcerative colitis. He has published in and reviews for prestigious journals including NEJM, Lancet, Gastroenterology and Gut. He sits on the editorial board of Inflammatory Bowel Diseases, JCC, APT, and the Canadian Journal of Gastroenterology.

He is presently the medical director for the Crohn’s and Colitis Canada (CCC) Calgary Chapter and sits on the Medical Advisory council for the Crohn’s and Colitis Foundation of Canada. He is the national chair of the CCC scholarship program. He has been awarded the highest honour, the Finkelstein award by Crohn’s and Colitis Canada for his work in the field of IBD. He is also an elected member of the International Organization of Inflammatory Bowel Disease (IOIBD) reflecting his status in the area. He was awarded the CAG Visiting Professor Award in 2016 for his contribution o the field of Gastroenterology in Canada. He is ranked amongst the top ten experts in the field worldwide ( He presently holds a senior leadership position within Alberta Health Services as the Medical Lead for Systems Integration with the mandate of improving the efficiency and quality of care that is delivered to patients.

Dr. Douglas Rex

Director of Colorectal Cancer

Dr. Douglas K. Rex is Distinguished Professor of Medicine at Indiana University School of Medicine, Chancellor’s Professor at Indiana University Purdue University Indianapolis, and Director of Endoscopy at Indiana University Hospital in Indianapolis. He graduated from Harvard College, Summa Cum Laude in 1976 and with highest distinction from Indiana University School of Medicine in 1980. He served as Chief Medical Resident at Indiana University Hospital and joined the faculty at Indiana University in 1985. He received the Outstanding Teacher Award in the Introduction to Medicine course five times and has been awarded the Indiana University School of Medicine Outstanding Teacher Award as well as Department of Medicine’s Excellence in Teaching Award. He is a full-time clinical gastroenterologist at Indiana University Hospital.

His major research interests have been in colorectal disease and, in particular, colorectal cancer screening and the technical performance of colonoscopy. He co-authored the colorectal cancer screening recommendations of the American College of Gastroenterology and the U.S. Multi-Society Task Force on Colorectal Cancer. He also authored the recommendations on quality in colonoscopy of the U.S. Multi-Society Task Force on Colorectal Cancer and the American College of Gastroenterology/American Society of Gastrointestinal Endoscopy. He has authored more than 200 original research papers, 55 book chapters, 200 invited papers, 40 editorials, and 40 guideline papers. He is an Associate Editor of Journal Watch Gastroenterology and serves on the editorial boards of 11 gastroenterology journals.

He is the current chair of the U.S. Multi-Society (ACG, ASGE, AGA, ACP-ASIM) Task Force on Colorectal Cancer. He has also served in the American College of Gastroenterology as Chairman of the Board of Governors and is a Past President of the ACG. He is a member of the Governing Board of ASGE and a recipient of the Rudolph V. Schindler Award from ASGE.

Dr. Michael Byrne

CEO & Founder

Dr. Michael Byrne provides senior leadership and clinical expertise to Satisfai Health and is a clinical innovator with over 20 years experience as a practicing physician. He is the founder of both Satisfai Health and its ai4gi joint venture. He is a Clinical Professor of Medicine in the Division of Gastroenterology at Vancouver General Hospital and UBC. He is also director of the Interventional Endoscopy Fellowship at VGH, and is the former Director of Endoscopy at VGH/UBC.

He has worked in the medical device space for several years. Prior to his role with Satisfai Health and his participation in the ai4gi project, he has worked with the Biotechnology Industry in several areas including colon cancer genetic testing, and novel applications of Photodynamic therapy for Gastrointestinal disease.

He is a graduate of Cambridge and Liverpool Universities. He has a strong research background in both basic science and clinical medicine with hands-on training in molecular sciene and pharmacology. He received an MD by thesis from the University of Cambridge for his work on Helicobacter Pylori and Cyclooxygenase. He also has a long track record of clinical research. Dr. Byrne has published extensively with over 90 peer reviewed publications and over 100 abstract presentations at National and International Meetings.

After several years working in the UK and Ireland, Dr. Byrne completed an Interventional Endoscopy Fellowship as well as working as an attending physician at Duke University Medical Center, North Carolina. He moved to his current role in Vancouver in 2003.

His main clinical interests are in the field of ERCP, interventional endoscopy, optical biopsy, colon cancer, pancreaticobiliary disease, and IBD.